Serum Polysialylated NCAM in Childhood Neuroblastoma
Author Information
Author(s): S Gluerl, C Schelp, N Madry, D von Schweinitzl, M Eckhardt, R Gerardy-Schahn
Primary Institution: Medical School Hannover
Hypothesis
Serum polysialylated NCAM levels can serve as a prognostic marker for childhood neuroblastoma.
Conclusion
Serum levels of polysialylated NCAM are significantly elevated in children with advanced neuroblastoma and decrease during successful therapy.
Supporting Evidence
- Serum levels of polysialylated NCAM were more than sixfold higher in children with advanced neuroblastoma.
- Serum concentrations correlated with the polysialylated NCAM content of the tumours.
- Serum levels decreased during successful therapy.
Takeaway
This study found that a special protein in the blood can help doctors see how serious a child's neuroblastoma is and if treatment is working.
Methodology
Serum levels of polysialylated NCAM were measured in 14 children with neuroblastoma and compared to 269 healthy controls using an immunoluminescence assay.
Limitations
The study had a small sample size and did not establish an age-dependent decrease in serum polysialylated NCAM.
Participant Demographics
14 children with neuroblastoma and 269 healthy control subjects aged 1 day to 16 years.
Want to read the original?
Access the complete publication on the publisher's website